Skip to main content
Have a personal or library account? Click to login
Global Epidemiology of Lung Cancer Cover

Global Epidemiology of Lung Cancer

Open Access
|Jan 2019

References

  1. Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncology. 2015; 1(4): 505527. DOI: 10.1001/jamaoncol.2015.0735
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin; 2015. DOI: 10.3322/caac.21262
  3. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. The New England Journal of Medicine. 2013; 368(4): 351364. DOI: 10.1056/NEJMsa1211127
  4. Youlden D, Cramb S and Baade P. The international epidemiology of lung cancer: Geographic distribution and secular trends. Journal of Thoracic Oncology. 2008; 3(8): 819831. DOI: 10.1097/JTO.0b013e31818020eb
  5. Jemal A, Center MM, DeSantis C and Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(8): 18931907. DOI: 10.1158/1055-9965.EPI-10-0437
  6. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. The Lancet Oncology. 2014; 15(5): 489538. DOI: 10.1016/S1470-2045(14)70029-4
  7. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014; 64(1): 929. DOI: 10.3322/caac.21208
  8. Freedman ND, Abnet CC, Caporaso NE, et al. Impact of changing US cigarette smoking patterns on incident cancer: Risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol; 2015.
  9. Meza R, Meernik C, Jeon J and Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS One. 2015; 10(3): e0121323. DOI: 10.1371/journal.pone.0121323
  10. Trinh QD, Nguyen PL, Leow JJ, et al. Cancer-specific mortality of Asian Americans diagnosed with cancer: A nationwide population-based assessment. J Natl Cancer Inst. 2015; 107(6). DOI: 10.1093/jnci/djv054
  11. Bach PB, Cramer LD, Warren JL and Begg CB. Racial differences in the treatment of early-stage lung cancer. New England Journal of Medicine. 1999; 341(16): 11981205. DOI: 10.1056/NEJM199910143411606
  12. Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi MC and Halm EA. Ethnic disparities in the treatment of stage I non–small cell lung cancer. American Journal of Respiratory and Critical Care Medicine. 2005; 171(10): 11581163. DOI: 10.1164/rccm.200411-1475OC
  13. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54(2): 7893. DOI: 10.3322/canjclin.54.2.78
  14. UK CR. Lung cancer incidence projections to 2024: Future rates and numbers of new cases in Great Britain and the UK. Cancer Stats Cancer Projections Series; 2009.
  15. Lortet-Tieulent J, Renteria E, Sharp L, et al. Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988–2010. European Journal of Cancer.
  16. Bray FI and Weiderpass E. Lung cancer mortality trends in 36 European countries: Secular trends and birth cohort patterns by sex and region 1970–2007. International Journal of Cancer. 2010; 126(6): 14541466. DOI: 10.1002/ijc.24855
  17. Torre LA, Siegel RL, Ward EM and Jemal A. International variation in lung cancer mortality rates and trends among women. Cancer Epidemiology Biomarkers & Prevention. 2014; 23(6): 10251036. DOI: 10.1158/1055-9965.EPI-13-1220
  18. Malvezzi M, Bosetti C, Rosso T, et al. Lung cancer mortality in European men: Trends and predictions. Lung Cancer. 2013; 80(2): 138145. DOI: 10.1016/j.lungcan.2013.01.020
  19. Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E. European cancer mortality predictions for the year 2014. Annals of Oncology; 2014. DOI: 10.1093/annonc/mdu138
  20. Gilhodes J, Belot A, Bouvier AM, et al. Incidence of major smoking-related cancers: Trends among adults aged 20–44 in France from 1982 to 2012. Cancer Epidemiol. 2015; 39(5): 707713. DOI: 10.1016/j.canep.2015.07.001
  21. Van der Heyden JHA, Schaap MM, Kunst AE, et al. Socioeconomic inequalities in lung cancer mortality in 16 European populations. Lung Cancer. 2009; 63(3): 322330. DOI: 10.1016/j.lungcan.2008.06.006
  22. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A population-based study, 2004–2007. Thorax. 2013; 68(6): 551564. DOI: 10.1136/thoraxjnl-2012-202297
  23. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5 – A population-based study. The Lancet Oncology. 2014; 15(1): 2334. DOI: 10.1016/S1470-2045(13)70546-1
  24. Francisci S, Minicozzi P, Pierannunzio D, et al. Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer (Oxford, England: 1990); 2015.
  25. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013. http://globocan.iarc.fr. Accessed July 18, 2014.
  26. Toyoda Y, Nakayama T, Ioka A and Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Japanese Journal of Clinical Oncology. 2008; 38(8): 534539. DOI: 10.1093/jjco/hyn072
  27. Woo T, Okudela K, Mitsui H, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathology International. 2012; 62(12): 785791. DOI: 10.1111/pin.12016
  28. O’Neill J. Building Better Global Economic BRICs; 2001(Global Economics Paper No: 66).
  29. Chatenoud L, Bertuccio P, Bosetti C, et al. Trends in cancer mortality in Brazil, 1980–2004. European Journal of Cancer Prevention. 2010; 19(2): 7986. DOI: 10.1097/CEJ.0b013e32833233be
  30. Souza MC, Vasconcelos AG and Cruz OG. Trends in lung cancer mortality in Brazil from the 1980s into the early 21st century: Age-period-cohort analysis. Cad Saude Publica; 2012 (1678-4464 [Electronic]).
  31. Singh N, Aggarwal AN, Gupta D, Behera D and Jindal SK. Unchanging clinico-epidemiological profile of lung cancer in North India over three decades. Cancer Epidemiology. 2010; 34(1): 101104. DOI: 10.1016/j.canep.2009.12.015
  32. Sharma PK and Bansal R. Profile of lung cancer in predominantly Bidi smoking rural population of northern Himachal Pradesh. Indian J Chest Dis Allied Sci. 2013; 55(2): 7578.
  33. Zhang Y, Tao S, Shen H and Ma J. Inhalation exposure to ambient polycyclic aromatic hydrocarbons and lung cancer risk of Chinese population. Proc Natl Acad Sci USA. (1091-6490 [Electronic]).
  34. Chen ZM, Peto R, Iona A, et al. Emerging tobacco-related cancer risks in China: A nationwide, prospective study of 0.5 million adults. Cancer. 2015; 121(Suppl 17): 30973106. DOI: 10.1002/cncr.29560
  35. She J, Yang P, Hong Q and Bai C. Lung cancer in China: Challenges and interventions. Chest. 2013; 143(4): 11171126. DOI: 10.1378/chest.11-2948
  36. Jemal A, Bray F, Forman D, et al. Cancer burden in Africa and opportunities for prevention. Cancer. 2012; 118(18): 43724384. DOI: 10.1002/cncr.27410
  37. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013. http://globocan.iarc.fr. Accessed October 29, 2014.
  38. Travis W, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6(2): 244285. DOI: 10.1097/JTO.0b013e318206a221
  39. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E and Bray F. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84(1): 1322. DOI: 10.1016/j.lungcan.2014.01.009
  40. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology; 2011 (1530-0285 [Electronic]).
  41. Travis WD. Pathology of lung cancer. Clinics in Chest Medicine. 2011; 32(4): 669692. DOI: 10.1016/j.ccm.2011.08.005
  42. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical Cancer Research. 2012; 18(22): 61696177. DOI: 10.1158/1078-0432.CCR-11-3265
  43. Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small cell lung cancer of adenocarcinoma histology (PIONEER). Journal of Thoracic Oncology. 2014; 9: 154162. DOI: 10.1097/JTO.0000000000000033
  44. Ou SH. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? Journal of Clinical Pathology. 2013; 66(10): 839846. DOI: 10.1136/jclinpath-2012-201296
  45. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research. 2008; 14(13): 42754283. DOI: 10.1158/1078-0432.CCR-08-0168
  46. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small cell lung cancer who harbor EML4-ALK. Journal of Clinical Oncology. 2009; 27(26): 42474253. DOI: 10.1200/JCO.2009.22.6993
  47. Brawley OW, Glynn TJ, Khuri FR, Wender RC and Seffrin JR. The first Surgeon General’s report on smoking and health: The 50th anniversary. CA Cancer J Clin. 2014; 64(1): 58. DOI: 10.3322/caac.21210
  48. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999; 91(14): 11941210. DOI: 10.1093/jnci/91.14.1194
  49. Boffetta P, Pershagen G, Jöckel K-H, et al. Cigar and pipe smoking and lung cancer risk: A multicenter study from Europe. Journal of the National Cancer Institute. 1999; 91(8): 697701. DOI: 10.1093/jnci/91.8.697
  50. Oberg M, Jaakkola MS, Woodward A, Peruga A and Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. Lancet. 2011; 377(9760): 139146. DOI: 10.1016/S0140-6736(10)61388-8
  51. IARC. Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2002; 83. Lyon, France.
  52. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. In: U.S. Department of Health and Human Services, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Rockville, MD; 2006.
  53. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. In: Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2010; Atlanta, GA.
  54. Agency USEP. Respiratory Health Effects of Passive Smoking (Also Known as Exposure to Secondhand Smoke or Environmental Tobacco Smoke—ETS). In: Agency USEP; 1992.
  55. Kim CH, Lee YA, Hung RJ, et al. Secondhand tobacco smoke exposure and lung adenocarcinoma in situ/minimally invasive adenocarcinoma (AIS/MIA). In: Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology; 2015. DOI: 10.1158/1055-9965.EPI-15-0436
  56. Abrams DB. Promise and peril of e-cigarettes: Can disruptive technology make cigarettes obsolete? JAMA. 2014; 311(2): 135136. DOI: 10.1001/jama.2013.285347
  57. Wang B, King BA, Corey CG, Arrazola RA and Johnson SE. Awareness and use of non-conventional tobacco products among U.S. students, 2012. American Journal of Preventive Medicine. 2014; 47(2, Supplement 1): S36S52. DOI: 10.1016/j.amepre.2014.05.003
  58. Agaku IT, King BA, Husten CG, et al. Tobacco product use among adults – United States, 2012–2013. Morbidity and Mortality Weekly Report. 2014; 63(25): 542547.
  59. Dutra LM and Glantz SA. Electronic cigarettes and conventional cigarette use among US adolescents: A cross-sectional study. JAMA Pediatrics. 2014; 168(7): 610617. DOI: 10.1001/jamapediatrics.2013.5488
  60. Kmietowicz Z. Use of e-cigarettes in UK has tripled in two years, finds survey. 2014; 348.
  61. Park SJ, Walser TC, Perdomo C, et al. Abstract B16: The effect of e-cigarette exposure on airway epithelial cell gene expression and transformation. Clinical Cancer Research. 2014; 20(2 Supplement): B16. DOI: 10.1158/1078-0432.14AACRIASLC-B16
  62. Kurmi OP, Arya PH, Lam K-BH, Sorahan T and Ayres JG. Lung cancer risk and solid fuel smoke exposure: A systematic review and meta-analysis. European Respiratory Journal. 2012; 40(5): 12281237. DOI: 10.1183/09031936.00099511
  63. Barone-Adesi F, Chapman RS, Silverman DT, et al. Risk of lung cancer associated with domestic use of coal in Xuanwei, China: Retrospective cohort study. BMJ (Clinical Research Ed.). 2012; 345: e5414. DOI: 10.1136/bmj.e5414
  64. Hosgood HD, 3rd, Boffetta P, Greenland S, et al. In-home coal and wood use and lung cancer risk: A pooled analysis of the International Lung Cancer Consortium. Environmental Health Perspectives. 2010; 118(12): 17431747. DOI: 10.1289/ehp.1002217
  65. Hosgood HD, Wei H, Sapkota A, et al. Household coal use and lung cancer: Systematic review and meta-analysis of case-control studies, with an emphasis on geographic variation. International Journal of Epidemiology. 2011; 40(3): 719728. DOI: 10.1093/ije/dyq259
  66. Tang L, Lim WY, Eng P, et al. Lung cancer in Chinese women: Evidence for an interaction between tobacco smoking and exposure to inhalants in the indoor environment. Environmental Health Perspectives. 2010; 118(9): 12571260. DOI: 10.1289/ehp.0901587
  67. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P and Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. European Respiratory Journal. 2009; 34(2): 380386. DOI: 10.1183/09031936.00144208
  68. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease – Incidence and predicting factors. Am J Respir Crit Care Med. 2011; 184(8): 913919. DOI: 10.1164/rccm.201103-0430OC
  69. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. American Journal of Respiratory and Critical Care Medicine. 2008; 178(7): 738744. DOI: 10.1164/rccm.200803-435OC
  70. Zulueta JJ, Wisnivesky JP, Henschke CI, et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012; 141(5): 12161223. DOI: 10.1378/chest.11-0101
  71. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: A pooled analysis from the International Lung Cancer Consortium. American Journal of Epidemiology. 2012; 176(7): 573585. DOI: 10.1093/aje/kws151
  72. Turner MC, Chen Y, Krewski D, Calle EE and Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never-smokers. American Journal of Respiratory and Critical Care Medicine. 2007; 176(3): 285290. DOI: 10.1164/rccm.200612-1792OC
  73. Young RP, Whittington CF, Hopkins RJ, et al. Chromosome 4q31 locus in COPD is also associated with lung cancer. European Respiratory Journal. 2010; 36(6): 13751382. DOI: 10.1183/09031936.00033310
  74. Brenner DR, McLaughlin JR and Hung RJ. Previous lung diseases and lung cancer risk: A systematic review and meta-analysis. PLoS ONE. 2011; 6(3): e17479. DOI: 10.1371/journal.pone.0017479
  75. Nelson HK and Kelsey KT. The molecular epidemiology of asbestos and tobacco in lung cancer. Oncogene. 2002; 21: 72847288. DOI: 10.1038/sj.onc.1205804
  76. Markowitz SB, Levin SM, Miller A and Morabia A. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. Am J Respir Crit Care Med. 2013; 188(1): 9096. DOI: 10.1164/rccm.201302-0257OC
  77. Olsson AC, Gustavsson P, Kromhout H, et al. Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med. 2011; 183(7): 941948. DOI: 10.1164/rccm.201006-0940OC
  78. Garshick E, Laden F, Hart JE, Davis ME, Eisen EA and Smith TJ. Lung cancer and elemental carbon exposure in trucking industry workers. Environmental Health Perspectives. 2012; 120(9): 13011306. DOI: 10.1289/ehp.1204989
  79. Silverman DT, Samanic CM, Lubin JH, et al. The diesel exhaust in miners study: A nested case-control study of lung cancer and diesel exhaust. Journal of the National Cancer Institute. 2012; 104(11): 855868. DOI: 10.1093/jnci/djs034
  80. Vermeulen R, Silverman DT, Garshick E, Vlaanderen J, Portengen L and Steenland K. Exposure-response estimates for diesel engine exhaust and lung cancer mortality based on data from three occupational cohorts. Environmental Health Perspectives. 2014; 122(2): 172177. DOI: 10.1289/ehp.1306880
  81. Christian WJ, Huang B, Rinehart J and Hopenhayn C. Exploring geographic variation in lung cancer incidence in Kentucky using a spatial scan statistic: Elevated risk in the Appalachian coal-mining region. Public Health Reports (Washington, D.C.: 1974). 2011; 126(6): 789796.
  82. Olsson A, Kromhout H, Agostini M, et al. A case-control study of lung cancer nested in a cohort of European asphalt workers. Environmental Health Perspectives. 2010; 118(10): 14181424. DOI: 10.1289/ehp.0901800
  83. Hogstedt C, Jansson C, Hugosson M, Tinnerberg H and Gustavsson P. Cancer incidence in a cohort of Swedish chimney sweeps, 1958–2006. American Journal of Public Health. 2013; 103(9): 17081714. DOI: 10.2105/AJPH.2012.300860
  84. Guha N, Merletti F, Steenland NK, Altieri A, Cogliano V and Straif K. Lung cancer risk in painters: A meta-analysis. Environmental Health Perspectives. 2010; 118(3): 303312. DOI: 10.1289/ehp.0901402
  85. De Matteis S, Consonni D, Lubin JH, et al. Impact of occupational carcinogens on lung cancer risk in a general population. International Journal of Epidemiology. 2012; 41(3): 711721. DOI: 10.1093/ije/dys042
  86. Vida S, Pintos J, Parent M-É, Lavoué J and Siemiatycki J. Occupational exposure to silica and lung cancer: Pooled analysis of two case-control studies in Montreal, Canada. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(6): 16021611. DOI: 10.1158/1055-9965.EPI-10-0015
  87. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). The Lancet Oncology. 2013; 14(9): 813822. DOI: 10.1016/S1470-2045(13)70279-1
  88. Hystad P, Demers PA, Johnson KC, Carpiano RM and Brauer M. Long-term residential exposure to air pollution and lung cancer risk. Epidemiology. 2013; 24(5): 762772.
  89. Raaschou-Nielsen O, Andersen ZJ, Hvidberg M, et al. Lung cancer incidence and long-term exposure to air pollution from traffic. Environmental Health Perspectives. 2011; 119(6): 860865. DOI: 10.1289/ehp.1002353
  90. Raaschou-Nielsen O, Bak H, Sørensen M, et al. Air pollution from traffic and risk for lung cancer in three Danish cohorts. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(5): 12841291. DOI: 10.1158/1055-9965.EPI-10-0036
  91. Carey IM, Atkinson RW, Kent AJ, van Staa T, Cook DG and Anderson HR. Mortality associations with long-term exposure to outdoor air pollution in a national English cohort. Am J Respir Crit Care Med. 2013; 187(11): 12261233. DOI: 10.1164/rccm.201210-1758OC
  92. Turner MC, Krewski D, Pope CA, 3rd, Chen Y, Gapstur SM and Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. Am J Respir Crit Care Med. 2011; 184(12): 13741381. DOI: 10.1164/rccm.201106-1011OC
  93. Pope CA, 3rd, Burnett RT, Turner MC, et al. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: Shape of the exposure-response relationships. Environmental Health Perspectives. 2011; 119(11): 16161621. DOI: 10.1289/ehp.1103639
  94. Oberoi S, Barchowsky A and Wu F. The global burden of disease for skin, lung and bladder cancer caused by arsenic in food. Cancer Epidemiology Biomarkers & Prevention; 2014. DOI: 10.1158/1055-9965.EPI-13-1317
  95. Ferreccio C, Yuan Y, Calle J, et al. Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer. Epidemiology. 2013; 24(6): 898905.
  96. Heck JE, Andrew AS, Onega T, et al. Lung cancer in a U.S. population with low to moderate arsenic exposure. Environmental Health Perspectives. 2009; 117(11): 17181723. DOI: 10.1289/ehp.0900566
  97. Turner MC, Krewski D, Chen Y, Pope CA, Gapstur S and Thun MJ. Radon and lung cancer in the American Cancer Society cohort. Cancer Epidemiology Biomarkers & Prevention. 2011; 20(3): 438448. DOI: 10.1158/1055-9965.EPI-10-1153
  98. Barros-Dios JM, Ruano-Ravina A, Pérez-Ríos M, Castro-Bernárdez M, Abal-Arca J and Tojo-Castro M. Residential radon exposure, histologic types, and lung cancer risk. A case-control study in Galicia, Spain. Cancer Epidemiology Biomarkers & Prevention. 2012; 21(6): 951958. DOI: 10.1158/1055-9965.EPI-12-0146-T
  99. Lam TK, Ruczinski I, Helzlsouer KJ, Shugart YY, Caulfield LE and Alberg AJ. Cruciferous vegetable intake and lung cancer risk: A nested case-control study matched on cigarette smoking. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(10): 25342540. DOI: 10.1158/1055-9965.EPI-10-0475
  100. Büchner FL, Bueno-de-Mesquita HB, Ros MM, et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(9): 22782286. DOI: 10.1158/1055-9965.EPI-10-0489
  101. Lam TK, Shao S, Zhao Y, et al. Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiology Biomarkers & Prevention. 2012; 21(12): 21762184. DOI: 10.1158/1055-9965.EPI-12-0745
  102. Mahabir S, Forman MR, Dong YQ, Park Y, Hollenbeck A and Schatzkin A. Mineral intake and lung cancer risk in the NIH-American Association of Retired Persons diet and health study. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(8): 19761983. DOI: 10.1158/1055-9965.EPI-10-0067
  103. Takata Y, Shu X-O, Yang G, et al. Calcium intake and lung cancer risk among female nonsmokers: A report from the Shanghai women’s health study. Cancer Epidemiology Biomarkers & Prevention. 2013; 22(1): 5057. DOI: 10.1158/1055-9965.EPI-12-0915-T
  104. Johansson M, Relton C, Ueland PM, et al. Serum B vitamin levels and risk of lung cancer. JAMA. 2010; 303(23): 23772385. DOI: 10.1001/jama.2010.808
  105. Cheng TY, Lacroix AZ, Beresford SA, et al. Vitamin D intake and lung cancer risk in the Women’s Health Initiative. The American Journal of Clinical Nutrition. 2013; 98(4): 10021011. DOI: 10.3945/ajcn.112.055905
  106. Yang WS, Va P, Wong MY, Zhang HL and Xiang YB. Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. The American Journal of Clinical Nutrition. 2011; 94(6): 15751583. DOI: 10.3945/ajcn.111.020966
  107. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine. 1994; 330(15): 10291035. DOI: 10.1056/NEJM199404143301501
  108. Fortmann SP, Burda BU, Senger CA, Lin JS and Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2013; 159(12): 824834. DOI: 10.7326/0003-4819-159-12-201312170-00729
  109. Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium. European Journal of Cancer. 2012; 48(13): 19571968. DOI: 10.1016/j.ejca.2012.01.038
  110. Matakidou A, Eisen T and Houlston RS. Systematic review of the relationship between family history and lung cancer risk. The British Journal of Cancer. 2005; 93(7): 825833. DOI: 10.1038/sj.bjc.6602769
  111. Lan Q, Hsiung CA, Matsuo K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics. 2012; 44(12): 13301335. DOI: 10.1038/ng.2456
  112. Wu X, Wang L, Ye Y, et al. Genome-wide association study of genetic predictors of overall survival for non–small cell lung cancer in never-smokers. Cancer Research. 2013; 73(13): 40284038. DOI: 10.1158/0008-5472.CAN-12-4033
  113. Schwartz AG, Prysak GM, Bock CH and Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2006; 28(3): 507518. DOI: 10.1093/carcin/bgl253
  114. Ohtsuka K, Ohnishi H, Kurai D, et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. Journal of Clinical Oncology. 2011; 29(8): e191e192. DOI: 10.1200/JCO.2010.31.4492
  115. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: A systematic review. JAMA. 2012; 307(22): 24182429. DOI: 10.1001/jama.2012.5521
  116. Aberle DR, Adams AM, Berg CD, et al. Reduced lung cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine. 2011; 365(5): 395409. DOI: 10.1056/NEJMoa1102873
  117. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). International Journal of Cancer. 2007; 120(4): 868874. DOI: 10.1002/ijc.22134
  118. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015; 191(10): 11661175. DOI: 10.1164/rccm.201408-1475OC
  119. Reich JM. A critical appraisal of overdiagnosis: Estimates of its magnitude and implications for lung cancer screening. Thorax. 2008; 63(4): 377383. DOI: 10.1136/thx.2007.079673
  120. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, lung, colorectal and ovarian cancer screening trial models and validation. Journal of the National Cancer Institute. 2011; 103(13): 10581068. DOI: 10.1093/jnci/djr173
  121. Etzel CJ and Bach PB. Estimating individual risk for lung cancer. Semin Respir Crit Care Med. 2011; 32(01): 003009. DOI: 10.1055/s-0031-1272864
  122. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. Journal of the National Cancer Institute. 2003; 95(6): 470478. DOI: 10.1093/jnci/95.6.470
  123. Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J and Albanes D. Validation of a model of lung cancer risk prediction among smokers. Journal of the National Cancer Institute. 2006; 98(9): 637640. DOI: 10.1093/jnci/djj163
  124. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. Journal of the National Cancer Institute. 2007; 99(9): 715726. DOI: 10.1093/jnci/djk153
  125. Cassidy A, Duffy SW, Myles JP, Liloglou T and Field JK. Lung cancer risk prediction: A tool for early detection. International Journal of Cancer. 2007; 120(1): 16. DOI: 10.1002/ijc.22331
  126. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: A case-control and cohort validation study. Annals of Internal Medicine. 2012; 157(4): 242250. DOI: 10.7326/0003-4819-157-4-201208210-00004
  127. Powell CA, Halmos B and Nana-Sinkam SP. Update in lung cancer and mesothelioma 2012. American Journal of Respiratory and Critical Care Medicine. 2013; 188(2): 157166. DOI: 10.1164/rccm.201304-0716UP
  128. Munafò MR, Timofeeva MN, Morris RW, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. Journal of the National Cancer Institute. 2012; 104(10): 740748. DOI: 10.1093/jnci/djs191
  129. Leng S, Do K, Yingling CM, et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clinical Cancer Research. 2012; 18(12): 33873395. DOI: 10.1158/1078-0432.CCR-11-3049
  130. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. Journal Article. 2011; 3(8): 495503. DOI: 10.1002/emmm.201100154
  131. Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012; 33(5): 10461054. DOI: 10.1093/carcin/bgs100
  132. Huang W, Hu J, Yang D-W, et al. Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. American Journal of Respiratory and Critical Care Medicine. 2012; 186(11): 11601167. DOI: 10.1164/rccm.201203-0534OC
  133. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences. 2011; 108(9): 37133718. DOI: 10.1073/pnas.1100048108
  134. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. Journal of Clinical Oncology. 2014; 32(8): 768773. DOI: 10.1200/JCO.2013.50.4357
  135. Pecot CV, Li M, Zhang XJ, et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiology Biomarkers & Prevention. 2012; 21(5): 786792. DOI: 10.1158/1055-9965.EPI-11-0932
  136. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW and Robertson JFR. Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice. Lung Cancer. 2014; 83(1): 5155. DOI: 10.1016/j.lungcan.2013.10.008
  137. Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. Journal of the National Cancer Institute. 2013; 105(18): 13851393. DOI: 10.1093/jnci/djt205
  138. Use of Biomarkers for Lung Cancer Screening. American Thoracic Society International Conference; 2014.
  139. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL and Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prevention Research. 2012; 5(8): 9921006. DOI: 10.1158/1940-6207.CAPR-11-0441
  140. Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR and Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest. 2013; 143(1): 123129. DOI: 10.1378/chest.12-1068
  141. Kligerman S and White C. Epidemiology of lung cancer in women: Risk factors, survival, and screening. AJR. American Journal of Roentgenology. 2011; 196(2): 287295. DOI: 10.2214/AJR.10.5412
  142. Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. Journal of the National Cancer Institute. 2004; 96(11): 826834. DOI: 10.1093/jnci/djh143
  143. Patel JD, Bach PB and Kris MG. Lung cancer in US women: A contemporary epidemic. JAMA. 2004; 291(14): 17631768. DOI: 10.1001/jama.291.14.1763
  144. Brinton LA, Gierach GL, Andaya A, et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiology Biomarkers & Prevention. 2011; 20(5): 900911. DOI: 10.1158/1055-9965.EPI-10-1325
  145. Baik CS, Strauss GM, Speizer FE and Feskanich D. Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the nurses’ health study. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(10): 25252533. DOI: 10.1158/1055-9965.EPI-10-0450
  146. Paulus JK, Asomaning K, Kraft P, Johnson BE, Lin X and Christiani DC. Parity and risk of lung cancer in women. American Journal of Epidemiology. 2010; 171(5): 557563. DOI: 10.1093/aje/kwp441
  147. Clague J, Reynolds P, Sullivan-Halley J, et al. Menopausal hormone therapy does not influence lung cancer risk: Results from the California teachers study. Cancer Epidemiology Biomarkers & Prevention. 2011; 20(3): 560564. DOI: 10.1158/1055-9965.EPI-10-1182
  148. Kabat GC, Miller AB and Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: A prospective cohort study. International Journal of Cancer. 2007; 120(10): 22142220. DOI: 10.1002/ijc.22543
  149. Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. Journal of the National Cancer Institute. 2010; 102(18): 14131421. DOI: 10.1093/jnci/djq285
  150. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): A post-hoc analysis of a randomised controlled trial. The Lancet. 374(9697): 12431251. DOI: 10.1016/S0140-6736(09)61526-9
  151. Simen-Kapeu A, Surcel H-M, Koskela P, Pukkala E and Lehtinen M. Lack of association between human papillomavirus type 16 and 18 infections and female lung cancer. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(7): 18791881. DOI: 10.1158/1055-9965.EPI-10-0356
  152. Shimazu T, Inoue M, Sasazuki S, et al. Plasma isoflavones and the risk of lung cancer in women: A nested case-control study in Japan. Cancer Epidemiology Biomarkers & Prevention. 2011; 20(3): 419427. DOI: 10.1158/1055-9965.EPI-10-1025
  153. Yang S-Y, Yang T-Y, Chen K-C, et al. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clinical Cancer Research. 2011; 17(8): 21492158. DOI: 10.1158/1078-0432.CCR-10-2045
  154. Nakamura H, Ando K, Shinmyo T, et al. Female gender is an independent prognostic factor in non–small cell lung cancer: A meta-analysis. Annals of Thoracic and Cardiovascular Surgery. 2011; 17(5): 469480. DOI: 10.5761/atcs.oa.10.01637
  155. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never-smokers. Journal of Clinical Oncology. 2007; 25(5): 472478. DOI: 10.1200/JCO.2006.07.2983
  156. Sun S, Schiller JH and Gazdar AF. Lung cancer in never smokers – A different disease. Nature Reviews. Cancer. 2007; 7(10): 778790. DOI: 10.1038/nrc2190
  157. Buell P and Dunn JE. Cancer mortality among Japanese ISSEI and NISEI of California. Cancer. 1965; 18(5): 656664. DOI: 10.1002/1097-0142(196505)18:5<;656::AID-CNCR2820180515>3.0.CO;2-3
  158. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non–small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6): 11211134. DOI: 10.1016/j.cell.2012.08.024
  159. Paik PK, Johnson ML, D’Angelo SP, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012; 118(23): 58405847. DOI: 10.1002/cncr.27637
  160. Warth A, Penzel R, Lindenmaier H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: Patient outcome, interplay with morphology and immunophenotype. European Respiratory Journal. 2014; 43(3): 872883. DOI: 10.1183/09031936.00018013
  161. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non–small cell lung cancers into routine clinical practice. Annals of Oncology. 2011; 22(12): 26162624. DOI: 10.1093/annonc/mdr489
  162. Solomon B, Varella-Garcia M and DR C. ALK Gene rearrangements – A new therapeutic target in a molecularly defined subset of non–small cell lung cancer. Journal of Thoracic Oncology. 2009; 4: 14501454. DOI: 10.1097/JTO.0b013e3181c4dedb
  163. Winstone TA, Man SF, Hull M, Montaner JS and Sin DD. Epidemic of lung cancer in patients with HIV infection. Chest. 2013; 143(2): 305314. DOI: 10.1378/chest.12-1699
  164. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Annals of Internal Medicine. 2008; 148(10): 728736. DOI: 10.7326/0003-4819-148-10-200805200-00005
  165. Kirk GD, Merlo C, O’Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clinical Infectious Diseases. 2007; 45(1): 103110. DOI: 10.1086/518606
  166. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS (London, England). 2012; 26(8): 10171025. DOI: 10.1097/QAD.0b013e328352d1ad
  167. Sigel K, Crothers K, Dubrow R, et al. Prognosis in HIV-infected patients with non–small cell lung cancer. British Journal of Cancer. 2013; 109(7): 19741980. DOI: 10.1038/bjc.2013.545
  168. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer. 2012; 118(1): 164172. DOI: 10.1002/cncr.26242
  169. Hooker CM, Meguid RA, Hulbert A, et al. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non–small cell lung cancer. The Annals of Thoracic Surgery. 2012; 93(2): 405412. DOI: 10.1016/j.athoracsur.2011.11.012
  170. Hessol NA, Martinez-Maza O, Levine AM, et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS (London, England). 2015; 29(10): 11831193. DOI: 10.1097/QAD.0000000000000690
DOI: https://doi.org/10.5334/aogh.2419 | Journal eISSN: 2214-9996
Language: English
Published on: Jan 22, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2019 Julie A. Barta, Charles A. Powell, Juan P. Wisnivesky, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.